Secondary Logo

Journal Logo

EDITORIAL INTRODUCTIONS

Editorial introductions

Section Editor(s): Schmidinger, Manuela; Margulis, Vitaly; Burger, Maximilian; Apolo, Andrea B.

doi: 10.1097/MOU.0000000000000212
  • Free

Current Opinion in Urology was launched in 1991. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of urology is divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

SECTION EDITORS

Manuela Schmidinger

Manuela Schmidinger

Manuela Schmidinger currently works in the Clinical Division of Oncology in Vienna. She has many qualifications including Specialist in Medical Oncology and Hematology and Specialist in Intensive Care Medicine. She graduated as a doctor from the University of Vienna, Medical School in 1992 and completed her internship in the Medical University of Vienna. Her speciality is in oncology, focusing on urology. She has written and co-authored several papers in her specialist area and this is her first year acting as section editor for Current Opinion in Urology.

Vitaly Margulis

Vitaly Margulis

Dr Vitaly Margulis is an Associate Professor of Urology at UT Southwestern Medical Center. He studied biology and biochemistry and graduated Summa Cum Laude before starting a Medical degree at UT Southwestern Medical School, Dallas, Texas. He later entered into a urologic oncology fellowship at the MD Anderson Cancer Center under mentorship of Dr Christopher G. Wood. He currently supervises a fully equipped and staffed basic science laboratory and has established a close working relationship with basic/translational scientists at The University of Texas Southwestern Medical Center in the department of Urology, Pathology and Medical Oncology. Here he collaborates with medical professionals and has the significant and unique capacity to study important aspects of biology of RCC carcinogenesis. He has received many awards such as the NIH Clinical Research Scientist LRP Award from the NIH and the Excellence in Urologic Pathology Award, as well as several Travel Grants from different institutes. He has worked on many peer-review publications and this is his first year acting as section editor for Current Opinion in Urology.

Maximilian Burger

Maximilian Burger

Maximilian Burger is Professor of Urology and Chairman of the Department of Urology of the University of Regensburg at the Caritas- St. Josef Medical Center, Regensburg, Germany. He is a Fellow of the European Board of Urology and his clinical and academical career has been centered on uro-oncology.

He was trained at the University Hospitals of Mainz, Germany, and Regensburg, Germany, and board certified in 2005. He commenced his academic career in the Dept. of Urology of the University in Regensburg chaired by Prof. Wolf-Ferdinand Wieland with clinical, uro-pathological and molecular studies on bladder cancer. He worked with the internationally renowned uro-pathologists Prof. Ferdinand Hofstädter and Prof. Arndt Hartmann of the University of Regensburg, Germany and internationally renowned uro-oncologist Prof. Shahrokh Shariat of Weill-Cornell Medical College and UT Southwestern, USA, and the University of Vienna, Austria.

He was appointed Assistant Professor and Consultant in 2007 and Assistant Professor and Managing Consultant (“Leitender Oberarzt”) of the Dept. of Urology and Pediatric Urology of the University of Würzburg chaired by Prof. Hubertus Riedmiller, an internationally outstanding expert in urinary diversion, in 2012. The main focus of his research was the definition of indications of radical surgery in early invasive bladder cancer. He joined the Guideline Panel on Non-muscle invasive Bladder Cancer of the European Association of Urology chaired by Prof. Marco Babjuk of Prague, Czech Republic, and the German S3 Guideline Panel on Bladder Cancer in 2012.

He was appointed Professor and Chairman of the Dept. of Urology of the University of Regensburg at the the Caritas- St. Josef Medical Center, Regensburg, Germany in 2013. He was elected board member and head of the Section Research Development of the o German Association of Urology (DGU) in 2014. He has authored and co-authored some 40 review articles with a cumulative IF exceeding 150 and more than 120 original manuscripts with a cumulative IF exceeding 500.

Andrea B. Apolo

Andrea B. Apolo

Dr Apolo is a Lasker Clinical Research Scholar, Tenure-Track Investigator and Chief of the Bladder Cancer Section in the Genitourinary Malignancies Branch of the National Cancer Institute. She received her M.D from Albert Einstein College of Medicine in New York. She then completed an internal medicine residency at New York-Presbyterian Hospital/Weill Cornell Medical Center followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr Apolo then joined the Medical Oncology Branch of the National Cancer Institute as an Assistant Clinical Investigator. She holds board certifications for the practice of Internal Medicine and Medical Oncology. Dr Apolo is also the genitourinary track leader of the education program committee and member of the scientific program committee of the American Society for Clinical Oncology (ASCO), a member of the bladder cancer program committee of the Society of Urologic Oncology (SUO) and the Chair of the Bladder Cancer Advocacy Network (BCAN) Think Tank Steering Committee.

Dr Apolo is dedicated to improving the lives of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Another research interest is improving tumor detection by developing new ways to image bladder and prostate cancer using new imaging modalities. Finally, Dr Apolo is interested in identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.